Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.

Sandoz has succeeded in convincing a Canadian court that its generic version of Rapaflo does not infringe a formulation patent for silodosin capsules, although the firm’s invalidity claims fell on deaf ears.

Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.